Pipeline Moves: Investigator-led oncology cell therapy trial terminated [Yahoo! Finance]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Yahoo! Finance
Meanwhile, a Phase II trial of Karyopharm Therapeutics's Xpovio (selinexor) was terminated in metastatic melanoma while Worg Pharmaceuticals Hangzhou's suspended a Phase II trial of WP-1302 in Grave's disease. On a positive note, Sention Therapeutics completed a Phase II trial of its pipeline candidate ST-1891 in hypothyroidism and a Phase II trial of Armata Pharmaceuticals's APPA-02 was completed in bronchiectasis. Lack of efficacy leads to termination of investigator-led oncology trial Iovance Biotherapeutics's cellular immunotherapy MDA-TIL for oncology saw a 24-point drop in its Phase Transition Success Rate (PTSR), falling to 7% in ovarian cancer following the termination of a Phase II investigator-led trial. The PTSR dropped by 16 points in colorectal cancer to 7% and 21 points in pancreatic ductal adenocarcinoma to 12%. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. The Phase I/II trial's ( N
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Therapeutics Announces the Appointment of Chief Accounting OfficerPR Newswire
- Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and ExpositionPR Newswire
- Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]Yahoo! Finance
KPTI
Earnings
- 11/5/24 - Beat
KPTI
Analyst Actions
- 11/1/24 - HC Wainwright
KPTI
Sec Filings
- 11/20/24 - Form 8-K
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- KPTI's page on the SEC website